Unfortunately, the second row was missing in table 1 of this article in the March 2017 issue of the European Respiratory Review. Please find the new row below. The study summarised in this row was also not cited where table 1 was introduced in the section “History, evolution and evidence for BPA”. Thus, a citation of reference [43] has been added as follows: “Published studies of BPA are discussed below and summarised in table 1 [9, 15–32, 43].” The article has been corrected and republished online.
TABLE 1.
Published results with balloon pulmonary angioplasty (BPA) in the management of patients with chronic thromboembolic pulmonary hypertension (CTEPH)
| First author, year [ref.] | Patients (location) | Procedures | CTEPH medical therapy pre-BPA | Mean age years | Reduction in mPAP mmHg | FC improvement | 6MWD improvement | Complications | Acute mortality (<30 days after BPA) | Long-term outcomes |
| Mizoguchi, 2012 [43] | 68 (Japan) | 255 sessions; 2–8 sessions per patient; 1–14 vessels dilated per session | 68/68 epoprostenol 1–5 ng·kg−1·min−1 for ∼5 days pre-BPA | 62.2±11.9 | 45.4±9.6 to 24±6.4 (p<0.01) | WHO FC 3.0 to 2.0 (p<0.01) |
296 to 368 m (p<0.01) | 76/255 sessions RPO 4/68 patients MV |
1 RHF, day 28 | 66/68 (97%) alive at 2.2±1.4 years |